Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
Identifieur interne : 006912 ( Ncbi/Curation ); précédent : 006911; suivant : 006913Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
Auteurs : Yun Fu [États-Unis] ; Debra Chung ; Minh-An Cao ; Sophia Apple ; Helena ChangSource :
- Annals of surgical oncology [ 1534-4681 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Aisselle (), Analyse de survie, Biopsie de noeud lymphatique sentinelle, Femelle, Humains, Indoles, Invasion tumorale, Lymphadénectomie (), Marqueurs biologiques tumoraux (sang), Mastectomie, Modèles de hasards proportionnels, Phénylpropionates, Radiothérapie adjuvante, Récepteur ErbB-2 (sang), Résultat thérapeutique, Sensibilité et spécificité, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein (), Tumeurs du sein (diagnostic), Tumeurs du sein (mortalité), Tumeurs du sein (radiothérapie), Tumeurs du sein (sang), Valeur prédictive des tests, Études de suivi, Études rétrospectives.
- MESH :
- diagnostic : Tumeurs du sein.
- mortalité : Tumeurs du sein.
- radiothérapie : Tumeurs du sein.
- sang : Marqueurs biologiques tumoraux, Récepteur ErbB-2, Tumeurs du sein.
- Adulte, Adulte d'âge moyen, Aisselle, Analyse de survie, Biopsie de noeud lymphatique sentinelle, Femelle, Humains, Indoles, Invasion tumorale, Lymphadénectomie, Mastectomie, Modèles de hasards proportionnels, Phénylpropionates, Radiothérapie adjuvante, Résultat thérapeutique, Sensibilité et spécificité, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Tumeurs du sein, Valeur prédictive des tests, Études de suivi, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Axilla (surgery), Biomarkers, Tumor (blood), Breast Neoplasms (blood), Breast Neoplasms (diagnosis), Breast Neoplasms (mortality), Breast Neoplasms (radiotherapy), Breast Neoplasms (surgery), Female, Follow-Up Studies, Humans, Indoles, Lymph Node Excision (methods), Mastectomy, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Phenylpropionates, Predictive Value of Tests, Proportional Hazards Models, Radiotherapy, Adjuvant, Receptor, ErbB-2 (blood), Retrospective Studies, Sensitivity and Specificity, Sentinel Lymph Node Biopsy, Survival Analysis, Treatment Outcome.
- MESH :
- chemical , blood : Biomarkers, Tumor, Receptor, ErbB-2.
- blood : Breast Neoplasms.
- diagnosis : Breast Neoplasms.
- methods : Lymph Node Excision.
- mortality : Breast Neoplasms.
- radiotherapy : Breast Neoplasms.
- surgery : Axilla, Breast Neoplasms.
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Indoles, Mastectomy, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Phenylpropionates, Predictive Value of Tests, Proportional Hazards Models, Radiotherapy, Adjuvant, Retrospective Studies, Sensitivity and Specificity, Sentinel Lymph Node Biopsy, Survival Analysis, Treatment Outcome.
Abstract
The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that axillary lymph node dissection (ALND) did not change the recurrence and overall survival (OS) rates in patients with lumpectomy and one to two positive nodes detected by sentinel lymph node biopsy (SLNB). The aim of this study was to determine whether patients with mastectomy and pathological N1 disease found by SLNB could forego ALND.
DOI: 10.1245/s10434-014-3814-3
PubMed: 25081336
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001418
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001418
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001418
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :006912
Links to Exploration step
pubmed:25081336Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?</title>
<author><name sortKey="Fu, Yun" sort="Fu, Yun" uniqKey="Fu Y" first="Yun" last="Fu">Yun Fu</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chung, Debra" sort="Chung, Debra" uniqKey="Chung D" first="Debra" last="Chung">Debra Chung</name>
</author>
<author><name sortKey="Cao, Minh An" sort="Cao, Minh An" uniqKey="Cao M" first="Minh-An" last="Cao">Minh-An Cao</name>
</author>
<author><name sortKey="Apple, Sophia" sort="Apple, Sophia" uniqKey="Apple S" first="Sophia" last="Apple">Sophia Apple</name>
</author>
<author><name sortKey="Chang, Helena" sort="Chang, Helena" uniqKey="Chang H" first="Helena" last="Chang">Helena Chang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25081336</idno>
<idno type="pmid">25081336</idno>
<idno type="doi">10.1245/s10434-014-3814-3</idno>
<idno type="wicri:Area/PubMed/Corpus">001418</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001418</idno>
<idno type="wicri:Area/PubMed/Curation">001418</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001418</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001418</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001418</idno>
<idno type="wicri:Area/Ncbi/Merge">006912</idno>
<idno type="wicri:Area/Ncbi/Curation">006912</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?</title>
<author><name sortKey="Fu, Yun" sort="Fu, Yun" uniqKey="Fu Y" first="Yun" last="Fu">Yun Fu</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgery, David Geffen School of Medicine, UCLA, Revlon/UCLA Breast Center, Los Angeles, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chung, Debra" sort="Chung, Debra" uniqKey="Chung D" first="Debra" last="Chung">Debra Chung</name>
</author>
<author><name sortKey="Cao, Minh An" sort="Cao, Minh An" uniqKey="Cao M" first="Minh-An" last="Cao">Minh-An Cao</name>
</author>
<author><name sortKey="Apple, Sophia" sort="Apple, Sophia" uniqKey="Apple S" first="Sophia" last="Apple">Sophia Apple</name>
</author>
<author><name sortKey="Chang, Helena" sort="Chang, Helena" uniqKey="Chang H" first="Helena" last="Chang">Helena Chang</name>
</author>
</analytic>
<series><title level="j">Annals of surgical oncology</title>
<idno type="eISSN">1534-4681</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Axilla (surgery)</term>
<term>Biomarkers, Tumor (blood)</term>
<term>Breast Neoplasms (blood)</term>
<term>Breast Neoplasms (diagnosis)</term>
<term>Breast Neoplasms (mortality)</term>
<term>Breast Neoplasms (radiotherapy)</term>
<term>Breast Neoplasms (surgery)</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Indoles</term>
<term>Lymph Node Excision (methods)</term>
<term>Mastectomy</term>
<term>Middle Aged</term>
<term>Neoplasm Invasiveness</term>
<term>Neoplasm Staging</term>
<term>Phenylpropionates</term>
<term>Predictive Value of Tests</term>
<term>Proportional Hazards Models</term>
<term>Radiotherapy, Adjuvant</term>
<term>Receptor, ErbB-2 (blood)</term>
<term>Retrospective Studies</term>
<term>Sensitivity and Specificity</term>
<term>Sentinel Lymph Node Biopsy</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Aisselle ()</term>
<term>Analyse de survie</term>
<term>Biopsie de noeud lymphatique sentinelle</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indoles</term>
<term>Invasion tumorale</term>
<term>Lymphadénectomie ()</term>
<term>Marqueurs biologiques tumoraux (sang)</term>
<term>Mastectomie</term>
<term>Modèles de hasards proportionnels</term>
<term>Phénylpropionates</term>
<term>Radiothérapie adjuvante</term>
<term>Récepteur ErbB-2 (sang)</term>
<term>Résultat thérapeutique</term>
<term>Sensibilité et spécificité</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tumeurs du sein ()</term>
<term>Tumeurs du sein (diagnostic)</term>
<term>Tumeurs du sein (mortalité)</term>
<term>Tumeurs du sein (radiothérapie)</term>
<term>Tumeurs du sein (sang)</term>
<term>Valeur prédictive des tests</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers, Tumor</term>
<term>Receptor, ErbB-2</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Lymph Node Excision</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Marqueurs biologiques tumoraux</term>
<term>Récepteur ErbB-2</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Axilla</term>
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Indoles</term>
<term>Mastectomy</term>
<term>Middle Aged</term>
<term>Neoplasm Invasiveness</term>
<term>Neoplasm Staging</term>
<term>Phenylpropionates</term>
<term>Predictive Value of Tests</term>
<term>Proportional Hazards Models</term>
<term>Radiotherapy, Adjuvant</term>
<term>Retrospective Studies</term>
<term>Sensitivity and Specificity</term>
<term>Sentinel Lymph Node Biopsy</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Aisselle</term>
<term>Analyse de survie</term>
<term>Biopsie de noeud lymphatique sentinelle</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indoles</term>
<term>Invasion tumorale</term>
<term>Lymphadénectomie</term>
<term>Mastectomie</term>
<term>Modèles de hasards proportionnels</term>
<term>Phénylpropionates</term>
<term>Radiothérapie adjuvante</term>
<term>Résultat thérapeutique</term>
<term>Sensibilité et spécificité</term>
<term>Stade de la tumeur</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tumeurs du sein</term>
<term>Valeur prédictive des tests</term>
<term>Études de suivi</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial reported that axillary lymph node dissection (ALND) did not change the recurrence and overall survival (OS) rates in patients with lumpectomy and one to two positive nodes detected by sentinel lymph node biopsy (SLNB). The aim of this study was to determine whether patients with mastectomy and pathological N1 disease found by SLNB could forego ALND.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006912 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 006912 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:25081336 |texte= Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25081336" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |